Newcastle, and archives branches at Norcross and Nelson), the health departments in Belfast, Dublin, Guernsey, Jersey, and the Isle of Man, and the Office of Population Censuses and Surveys; and Dr P Fraser and other members of the Environmental Monitoring Unit of the Medical Research Council. We also thank all those who provided lists of independent respondents—namely, the British Atomic Veterans Association, the British Nuclear Test Veterans Association, the Royal British Legion, the British Broadcasting Corporation, the Department of Social Medicine of the University of Birmingham, Oxford Eye Hospital, the Institution of Professional Civil Servants, the Association of Scientific Technical and Managerial Staffs, and various government departments. Other staff from the National Radiological Protection Board, the Imperial Cancer Research Fund, and the University of Oxford whose help we acknowledge include Steve Barry, Debbie Belcher, Sharon Bowler, Andrew Brown, Cathy Harwood, Mark Hillier, Gladys Lane, Christine Lees, Thora Mould, Louise Ogden, Carole Pearce, Stewart Rae, Steve Rees, Gill Saw, Lynda Smith, Irene Stratton, Val Weare, Sir David Weatherall, and Michael Yeats. Finally, we wish to record the contribution made by the late Dr John Reissland during the planning of this study.

References

- 1 Reissland J. *Protocol for a study of the health of UK participants in the UK atmospheric nuclear weapon tests*. London: HMSO, 1983. (NRPB-R154.)
- 2 Darby SC, Kendall GM, Fell TP, et al. *Mortality and cancer incidence in UK participants in UK atmospheric nuclear weapon tests and experimental programmes*. London: HMSO, 1988. (NRPB-R214.)

- 3 Office of Population Censuses and Surveys. *The National Health Service central register as an aid to medical research. A guide for potential applicants*. London: OPCS, 1982.
- 4 World Health Organisation. *Manual of the international statistical classification of diseases, injuries and causes of death*. 9th revision. Geneva: WHO, 1977.
- 5 Breslow NE, Day NE. *Statistical methods in cancer research*. Vol II. The analysis of cohort studies. Lyons: International Agency for Research on Cancer, 1987.
- 6 Fox AJ, Collier PF. Low mortality rates in industrial cohort studies due to selection for work and survival in the industry. *British Journal of Preventive and Social Medicine* 1976;30:225-30.
- 7 Preston DL, Kato H, Kopecky KJ, Fujita S. *Life span study report 10. Part I. Cancer mortality among A-bomb survivors in Hiroshima and Nagasaki 1950-82*. Hiroshima: Radiation Effects Research Foundation, 1986. (RERF TRI-86.)
- 8 Darby SC, Doll R, Gill SK, Smith PG. Long term mortality after a single treatment course with x-rays in patients treated for ankylosing spondylitis. *Br J Cancer* 1987;55:179-90.
- 9 United Nations Scientific Committee on the Effects of Atomic Radiation. *Sources and effects of ionizing radiation*. New York: United Nations, 1977.
- 10 International Commission on Radiological Protection. *Recommendations of the International Commission on Radiological Protection*. Oxford: Pergamon Press, 1977. (ICRP publication No 26.)
- 11 Robinette CD, Jablon S, Preston DL. *Studies of participants in nuclear tests*. Final report. Washington: National Research Council Medical Follow-up Agency, 1985.
- 12 Gilbert ES, Marks S. An analysis of the mortality of workers in a nuclear facility. *Radiat Res* 1979;79:122-48.
- 13 Smith PG, Douglas AJ. Mortality of workers at the Sellafield plant of British Nuclear Fuels. *Br Med J* 1986;293:845-54.
- 14 Cuzick J. Radiation-induced myelomatosis. *N Engl J Med* 1981;304:204-10.
- 15 Heath CW, Jr. The leukaemias. In: Schottenfeld D, Fraumeni JF Jr, eds. *Cancer epidemiology and prevention*. Philadelphia: W B Saunders, 1982:728-38.
- 16 Blattner WA. Multiple myeloma and macroglobulinaemia. In: Schottenfeld D, Fraumeni JF Jr, eds. *Cancer epidemiology and prevention*. Philadelphia: W B Saunders, 1982:795-813.
- 17 Beral V, Inskip H, Fraser P, Booth M, Coleman D, Rose G. Mortality of employees of the United Kingdom Atomic Energy Authority, 1946-1979. *Br Med J* 1985;291:440-7.

(Accepted 21 December 1987)

SHORT REPORTS

Microproteinuria: response to operation

Microalbuminuria is accepted as a sensitive indicator of diabetic nephropathy. In diabetes proteinuria is associated with a greater incidence of arterial disease and higher mortality,¹ and microalbuminuria with a general increase in vascular permeability.² A transient increase in urinary excretion of protein and albumin occurs within four hours after burns and trauma.³ It is proportional to the severity of injury, recurs with complications such as sepsis, and may reflect a general increase in vascular permeability as part of the acute phase response.^{3,4} Vascular permeability increases within three hours of the start of operations⁵ and might therefore be accompanied by an increase in urinary protein excretion. To establish whether this was so we measured protein excretion in patients before and after various operations.

Patients, methods, and results

We studied 33 patients, of whom 21 had indwelling bladder catheters. Eleven patients were having intraperitoneal operations (elective repair of an aortic aneurysm (five), resections of the large bowel (five) and cholecystectomy (one)); 13 were having extraperitoneal operations (femorodistal arterial reconstruction (11) and repair of an inguinal hernia (two)); and nine were having high ligation of the saphenous vein under local anaesthesia. Urine was obtained within the two hours before and three hours after the operation in all patients. Urinary total protein and albumin excretion was measured as described previously⁴ and expressed as mg/mmol creatinine to correct for changes in dilution.

After operation the urinary total protein concentration increased in all 33 patients and urinary albumin concentration increased in 29 patients (four patients undergoing ligation of the saphenous vein did not show an increase). The geometric mean urinary total protein concentration increased 4.37-fold (95% confidence interval 2.28 to 8.34; geometric mean 6.5 (range 0.9-55.7) mg/mmol creatinine before operation and 28.6 (2.5-462) mg/mmol after). The geometric mean urinary albumin increased 3.10-fold (95% confidence interval 1.69 to 5.66; geometric mean 1.3 (range 0.4-8.5) mg/mmol before operation and 4.1 (0.3-62.6) mg/mmol after). The arithmetic mean urinary total protein concentration in the nine patients operated on under local anaesthesia increased from 4.4 (range 0.9-12.6) mg/mmol creatinine before operation to 7.2 (2.5-23.0) mg/mmol after operation, ($p < 0.05$, Wilcoxon's signed rank test). The arithmetic mean urinary albumin concentration in these nine patients did not change significantly (mean 0.9 (range 0.2-2.4) mg/mmol creatinine before and 0.8 (0.3-2.0) mg/mmol after operation).

In two patients undergoing resections of the large bowel, one elective repair of an aortic aneurysm, and one axillobifemoral grafting with bilateral femorodistal arterial reconstruction urine samples were collected 15 minutes before the operation and every 30 minutes after the start of the operation. The mean time to significant increase in urinary total protein or albumin concentration was 1.5

(range 0.5-2.5) hours. The figure shows serial urinary concentrations of total protein and albumin in a 62 year old man with Crohn's disease who underwent resection for an enteroenteric fistula.

Excretion of urinary total protein and albumin during laparotomy and bowel resection. (Mean total protein and albumin concentrations in 20 healthy subjects were 3.9 (SD 1.3) and 0.5 (0.6) mg/mmol creatinine respectively.)

Comment

All 33 patients showed increases in urinary total protein concentration, and 29 in urinary albumin concentration, by three hours after their operation; the figure shows the rapidity and magnitude of the changes. Measurement of urinary proteins in four patients before and after catheterisation and induction of general anaesthesia showed no change in concentration. Three patients who had major operations but did not have catheters inserted showed appreciable increases in urinary total protein and albumin concentrations, suggesting that the phenomenon is independent of catheterisation. There were no differences between men and women or

between patients having abdominal or other operations. Minor operations under local anaesthesia resulted in smaller but significant increases in urinary total protein but not albumin concentrations, supporting the observation made in patients with trauma that the magnitude of proteinuria is related to the severity of injury.

We conclude that operations are associated with a rapid increase in urinary protein excretion, and major operations with microalbuminuria, and suggest that this reflects changes in vascular permeability. The usefulness of measurements of protein excretion in predicting postoperative complications needs to be established.

- 1 Winocour PH, Durrington PN, Ishola M, Anderson DC, Cohen H. Influence of proteinuria on vascular disease, blood pressure, and lipoproteins in insulin dependent diabetics. *Br Med J* 1987;294:1648-51.
- 2 Feldt-Rasmussen B. Increased transcapillary escape rate of albumin in type 1 (insulin-dependent) diabetic patients with microalbuminuria. *Diabetologia* 1986;29:282-6.
- 3 Gosling P, Sutcliffe AJ, Cooper MACS, Jones AF. Burn and trauma associated proteinuria: the role of lipid peroxidation, renin, and myoglobin. *Ann Clin Biochem* (in press).
- 4 Gosling P, Sutcliffe AJ. Proteinuria following trauma. *Ann Clin Biochem* 1986;23:681-5.
- 5 Fleck A, Raines G, Hawker F, et al. Increased vascular permeability: a major cause of hyposalbuminuria in disease and injury. *Lancet* 1985;i:781-4.

(Accepted 23 September 1987)

Departments of Biochemistry and Surgery, Selly Oak Hospital, Birmingham B29 6JD

PETER GOSLING, PHD, MRCPATH, principal biochemist
CLIFFORD P SHEARMAN, FRCS, research registrar
BRIAN R GWYNN, FRCS, senior registrar
MALCOLM H SIMMS, FRCS, consultant surgeon

Department of Surgery, Sandwell General Hospital, West Midlands B71 4HJ
EDWARD T BAINBRIDGE, FRCS, consultant surgeon

Correspondence to: Dr Gosling.

Itraconazole as maintenance treatment for cryptococcal meningitis in the acquired immune deficiency syndrome

Cryptococcal meningitis is a life threatening opportunistic infection with a prevalence among patients with the acquired immune deficiency syndrome (AIDS) of 2.0-7.5%. Combination treatment with intravenous amphotericin B and oral flucytosine for six weeks is the treatment of choice.¹ Maintenance treatment is necessary subsequently as relapses often occur in immunodeficient patients.²

Itraconazole is a new antifungal triazole chemically related to drugs derived from imidazole such as ketoconazole. After induction treatment we used oral itraconazole to prevent relapse of cryptococcal meningitis in patients with AIDS.

Patients, methods, and results

Five patients positive for antibody to human immunodeficiency virus (HIV) entered the open study. In all patients *Cryptococcus neoformans* had been isolated in cultures of cerebrospinal fluid, fulfilling the diagnostic criteria of the Centers for Disease Control for AIDS. Each patient received induction treatment with amphotericin B given intravenously (0.3 mg/kg/day) and oral flucytosine (150 mg/kg/day every six hours) for six to eight weeks. In four patients (cases 1, 2, 4, 5) maintenance treatment was with oral itraconazole 100 mg twice a day. One patient (case 3) received a higher dose of itraconazole (400 mg/day) because of its interaction with rifampicin, which was being taken simultaneously. The patient in case 1 was initially given maintenance treatment with amphotericin B (20 mg intravenously once a week) for six months before receiving oral itraconazole.

During treatment the titre of cryptococcal antigen in the cerebrospinal fluid was monitored by latex agglutination (Netherlands Reference Laboratory for Bacterial Meningitis) and the presence of viable cryptococci was assessed. Patients were considered to be responding well if clinical improvement con-

Effect of maintenance treatment with itraconazole on cryptococcal infection in five patients with the acquired immune deficiency syndrome

Case No	Titre of cryptococcal antigen		Follow up (months)	Dose of itraconazole (mg/day)
	Before treatment	During treatment		
1	1/128	1/16	3	200*
2	1/2048	1/32	12	200
3	1/1024	1/32	12	400
4	1/128	1/16	10	200
5	1/32	Not done	3	200

*Maintenance treatment comprised amphotericin B 20 mg intravenously once a week for first six months after induction treatment.

tinued, cerebrospinal fluid remained or became sterile, and the titre of cryptococcal antigen in the cerebrospinal fluid declined.

Before maintenance treatment was started titres of cryptococcal antigen ranged from 1/32 to 1/2048 (table) and in all patients cultures of cerebrospinal fluid did not yield any growth, although encapsulated yeasts were still present on microscopic examination of the cerebrospinal fluid. In four patients the titre of cryptococcal antigen declined during treatment (table). One patient (case 5) refused re-examination of cerebrospinal fluid. He died three months later from a severe AIDS dementia complex without clinical evidence of relapse of cryptococcal meningitis. Another patient (case 1) died of disseminated infection with *Mycobacterium avium intracellulare* after three months of maintenance treatment, and a third patient (case 3) died after 12 months of pneumonia caused by *Pseudomonas aeruginosa*; in both cases cultures of cerebrospinal fluid were sterile before death. Two patients were still alive after 10 and 12 months of maintenance treatment.

We did not observe any side effects during treatment with itraconazole.

Comment

As with other infectious complications in AIDS that can be treated the risk of relapse of cryptococcal meningitis after an initial response to treatment is high. Maintenance treatment with amphotericin B 80-100 mg each week is now recommended,³ but it necessitates inpatient care, is often poorly tolerated, and gives frequent toxicity. Flucytosine cannot be used in maintenance treatment because of rapid development of resistance. High dose oral ketoconazole has been beneficial in preventing relapse. Itraconazole and fluconazole are new antifungal triazoles. Itraconazole has a much lower minimal inhibitory concentration for *C. neoformans* than fluconazole in vitro.⁴ In pharmacokinetic studies fluconazole penetrated the cerebrospinal fluid extremely well whereas cerebrospinal fluid concentrations of itraconazole were very low or not detectable.⁵ Both agents seemed to be equally active at similar doses in rabbits with cryptococcal meningitis.⁴

The results of this study suggest that long term treatment with oral itraconazole is effective in preventing relapse of cryptococcal meningitis in patients with AIDS. The drug can be tolerated for long periods without side effects. A clinical trial of itraconazole as induction treatment is now in progress.

- 1 Bennett JE, Dismukes WE, Duma RJ, et al. A comparison of amphotericin B alone and combined with flucytosine in the treatment of cryptococcal meningitis. *N Engl J Med* 1979;301:126-31.

- 2 Kovacs JA, Kovacs AA, Polis M, et al. Cryptococcosis in the acquired immunodeficiency syndrome. *Ann Intern Med* 1985;103:533-8.

- 3 Zuger A, Louie E, Holzman RS, Simberloff MS, Rahal JJ. Cryptococcal disease in patients with the acquired immunodeficiency syndrome. *Ann Intern Med* 1986;104:234-40.

- 4 Perfect JR, Savani DV, Durack DT. Comparison of itraconazole and fluconazole in treatment of cryptococcal meningitis and candida pyelonephritis in rabbits. *Antimicrob Agents Chemother* 1986;29:579-83.

- 5 Perfect JR, Durack DT. Penetration of imidazoles and triazoles into cerebrospinal fluid of rabbits. *J Antimicrob Chemother* 1985;16:81-6.

(Accepted 9 September 1987)

Departments of Neurology, Internal Medicine, and Microbiology, Academic Hospital at the University of Amsterdam, 1105 AZ Amsterdam, The Netherlands

J DE GANS, MD, neurologist

J K M EEF TINCK SCHATTENKERK, MD, internist

R J VAN KETEL, MD, senior microbiologist

Correspondence to: Dr de Gans.